Market Intelligence Resource | April 22, 2024
FDA Approval Summary For Rejoyn Device
On March 30, 2024, the U.S. Food and Drug Administration (FDA) published this notice to Otsuka America. The notice grants marketing approval for the Rejoyn device, a prescription digital therapeutic to be used as adjunct treatment for major depressive disorder . . .
